帕曲妥单抗

帕曲妥单抗（INN：Patritumab）是一种人单克隆抗体，设计用于治疗非小细胞肺癌（英语：Non-small-cell lung cancer）。它充当免疫调节剂。^[1]^[2]

临床试验

它正在进行针对头颈部鳞状细胞癌的二期临床试验。^[3]

它将被纳入I-SPY 2乳腺癌试验的新组中。^[4]

^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 (PDF). WHO Drug Information. 2011, 25 (4).
^ Horinouchi H. The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy. December 2016, 16 (12): 1549–1555. PMID 27744717. S2CID 4035336. doi:10.1080/14712598.2016.1249846.
^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
^ Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer. October 2016.